Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC
Authors
Antonia, SVillegas, A
Daniel, D
Vicente, D
Murakami, S
Hui, R
Kurata, T
Chiappori, A
Lee, KH
de Wit, M
Cho, BC
Bourhaba, M
Quantin, X
Tokito, T
Mekhail, T
Planchard, D
Kim, Y
Karapetis, C
Hiret, S
Ostoros, G
Kubota, K
Gray, J
Paz-Ares, L
De Carpeno, JDC
Faivre-Finn, Corinne
Reck, M
Vansteenkiste, J
Spigel, D
Wadsworth, C
Taboada, M
Dennis, P
Ozguroglu, M
Affiliation
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL/USIssue Date
2018
Metadata
Show full item recordCitation
Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. PL02.01 Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. J Thorac Oncol. 2018;13(10):S184.Journal
Journal of Thoracic OncologyDOI
10.1016/j.jtho.2018.08.010Additional Links
https://dx.doi.org/10.1016/j.jtho.2018.08.010Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.jtho.2018.08.010